Meta faces April trial in FTC case seeking to unwind Instagram mergerCalifornia has been lately in the business of blowing up dams. So a decision to actually raise one is big news. In a deal approved by eight water agencies as well as the federal government, the San Luis Reservoir between Gilroy and Los Banos, the fifth-largest reservoir in the state, . Already at 382 feet, the added height will increase storage by 130,000 acre feet. That’s roughly the amount of water that would be consumed by 650,000 people in one year. Matthew Keller, ​​a spokesperson for the Santa Clara Valley Water District, one of the eight agencies, called it “ ,” which is no embellishment in a state that has made dam removal a centerpiece of its identity. In fact, California orchestrated the largest dam removal project in U.S. history: the dismantling of four hydroelectric dams on the Klamath River near the Oregon border. Gov. Gavin Newsom called it “a monumental achievement,” and not only for the river “but for our entire state, nation and planet.” A Showdown Over Water and Delta Smelt A month after Newsom made that statement, the country elected Donald Trump for another term in the White House, setting up what is likely to be a bitter confrontation over water. Trump, of course, has a different view of water in California than does the ruling class in Sacramento and in the big cities. The latter sees only scarcity, but Trump sees abundance. During his campaign, he “promised Californians unprecedented access to water and reduced protections for a key fish species if he is reelected,” in September. Thirty-five million Californians , including farmers in the Central Valley — known as the “nation’s breadbasket” because it is one of the most productive agricultural regions on Earth — are denied water due to the struggle over a “key fish.” The rare, tiny Delta smelt looms “ ,” John Durand, a University of California, Davis, researcher told the British Guardian in 2019. It’s truly a matter of “ .” Writing in the California WaterBlog, environmental sociologist Caleb Scoville explains how a creature that typically measures has become a heated subject far beyond the state’s borders. “​​The dynamics and character of the Delta smelt controversy are better explained by national partisan divisions than as a regional struggle for access to water,” says Scoville. In other words, the Delta smelt is a proxy war between the blue agenda and red policies. Get Ready for the Rhetoric to Ramp Up With all the politics swirling over a small fish that is “ ” and “only occurs in the San Francisco Estuary,” there is bound to be a fusillade of rhetorical bombs lobbed from Sacramento to Washington and back over the next four years. If Trump follows up where he left off, one of his first acts his second time around is likely to be pumping more water through the ​​Central Valley Project, a federal Bureau of Reclamation . During his first term, Trump ordered the project to increase water delivery downstream. By 2020, flow southward had increased by about 5% due to Trump’s policies. But his agenda ran into environmentalist and political resistance, and a different administration, which critics have called “ ,” that did not see things the same way. Now he has to begin again, from the top, so to speak. Another project thought to be in Trump’s lineup is expanding the largest reservoir in the state, Lake Shasta. It was on his list in 2020. An environmental report that year looked at the feasibility of raising the dam by 18.5 feet, which would lift the lip by 3%, and increase the storage capacity “by 634,000 acre-feet, or more than 200 billion gallons,” enough, says the Bureau of Reclamation, “ .” While Sacramento is aligned against him — Newsom has called a special session to “safeguard California values” and “Trump-proof” the state — the thirsty farmers of the Central Valley, who feed not only the country but their own families from the slim profits they make, tend to favor Trump’s agenda — for obvious reasons. But then they’ve long been accustomed to getting better treatment from politicians outside the state.

geothermal turbines market which was USD 67.61 billion in 2023, would rocket up to USD 111.89 billion by 2031, and is expected to undergo a CAGR of 6.5% 11-22-2024 06:59 PM CET | Advertising, Media Consulting, Marketing Research Press release from: Data Bridge Market Research Private Ltd / PR Agency: Data Bridge Market Research "Global Geothermal Turbines Market, By Type (Flash Steam, Binary Cycle, and Dry Steam), Capacity (Low Capacity (10MW)), Application (Electric Power Generation, Direct Use, and Cogeneration), End Use (Industrial, Residential, Agriculture, and Others) - Industry Trends and Forecast to 2031. Data Bridge Market Research analyses that the global geothermal turbines market which was USD 67.61 billion in 2023, would rocket up to USD 111.89 billion by 2031, and is expected to undergo a CAGR of 6.5% during the forecast period of 2024 to 2031. Explore Further Details about This Research Geothermal Turbines Market Share Report https://www.databridgemarketresearch.com/reports/global-geothermal-turbines-market **Middle East Respiratory Syndrome (MERS) Market Analysis 2021 & 2029** **2021 Analysis:** - The Middle East Respiratory Syndrome (MERS) market in 2021 witnessed steady growth with an increasing focus on research and development efforts to combat the disease. The market was primarily driven by the rising prevalence of MERS infections in the Middle Eastern region, leading to a higher demand for diagnostic tools, treatment options, and preventive measures. The market also saw advancements in technology and innovations in therapeutic approaches to manage MERS. **2029 Analysis:** - By 2029, the Middle East Respiratory Syndrome (MERS) market is projected to experience significant growth due to continued research and development activities aimed at finding more effective treatment modalities and preventive strategies. With an increasing emphasis on public health initiatives and infrastructure development in the Middle East, the market is expected to expand further, offering new opportunities for market players to introduce innovative solutions. **Segments:** - **Diagnostic Tools** - Advanced PCR testing kits - Rapid antigen detection assays - Serology tests - **Treatment Options** - Antiviral medications - Immunomodulators - **Preventive Measures** - Vaccines targeting MERS-CoV - Public health campaigns on hygiene practices **Market Players:** - **Abbott Laboratories** - **Roche Diagnostics** - **Tetracore Inc.** - **Siemens Healthineers** - **Thermo Fisher Scientific** - **Cepheid** - **Fujirebio** - **BioFire Diagnostics** - **Qiagen** - **Biocartis** https://www.databridgemarketresearch.com/reports/global-middle-east-respiratory-syndrome-mers-marketThe Middle East Respiratory Syndrome (MERS) market is poised for significant growth between 2021 and 2029 as key market players continue to invest in research and development efforts to combat the disease effectively. With advancements in technology and therapeutic approaches, there is a growing focus on developing more precise and rapid diagnostic tools to detect MERS infections early on. This emphasis on early detection is crucial in controlling the spread of the disease and reducing the overall burden on healthcare systems in the Middle East region. In terms of treatment options, the market is witnessing a shift towards innovative antiviral medications and immunomodulators that target the specific mechanisms of MERS-CoV, the virus responsible for the syndrome. These novel therapies offer promising outcomes in managing the symptoms of MERS and improving patient outcomes. Additionally, preventive measures such as vaccines targeting MERS-CoV and public health campaigns promoting hygiene practices are becoming increasingly crucial in preventing the spread of the disease and minimizing its impact on public health. Market players such as Abbott Laboratories, Roche Diagnostics, Tetracore Inc., and Siemens Healthineers are at the forefront of developing cutting-edge solutions for the MERS market. These companies are leveraging their expertise in diagnostics, treatment development, and public health initiatives to address the evolving needs of healthcare systems in the Middle East. Collaborative efforts among industry players are also driving innovation and propelling the market forward by introducing new products and solutions that cater to the specific requirements of combating MERS effectively. Moreover, with the growing emphasis on infrastructure development and public health initiatives in the Middle East, there is a ripe opportunity for market players to expand their reach and introduce their offerings to a broader audience. The increasing awareness about MERS and the importance of early detection and treatment among healthcare providers and the general population is creating a conducive environment for market growth. As a result, the Middle East Respiratory Syndrome market is expected to witness a surge in demand for diagnostic tools, treatment options, and preventive measures, presenting lucrative opportunities for**Market Players:** - GeneOne Life Science (South Korea) - INOVIO Pharmaceuticals (U.S.) - Pfizer Inc. (U.S.) - Regeneron Pharmaceuticals Inc (U.S.) - Astellas Pharma Inc. (Japan) - Merck KGaA (Germany) - Sanofi (France) - Biocare Medical, LLC (U.S.) - Lilly (U.S.) - Teva Pharmaceutical Industries Ltd (Israel) The Middle East Respiratory Syndrome (MERS) market is witnessing substantial growth driven by the concerted efforts of key market players in research, development, and innovation. With a focus on developing advanced diagnostic tools, treatment options, and preventive measures, the market is poised to expand significantly between 2021 and 2029. Collaborative efforts among industry leaders such as Abbott Laboratories, Roche Diagnostics, Tetracore Inc., and Siemens Healthineers are paving the way for cutting-edge solutions to combat MERS effectively. These companies are leveraging their expertise to introduce novel therapies, diagnostic kits, and public health initiatives tailored to the unique requirements of the Middle Eastern region. The shift towards more precise diagnostic tools, including PCR testing kits and rapid antigen detection assays, is crucial for early detection of MERS infections, thereby aiding in containing the spread of the disease and reducing the strain on healthcare systems. Additionally, the market is witnessing a transition towards innovative treatment options such as antiviral medications and immunomodulators that target the specific mechanisms of M Table Of Content 1 Introduction 1.1 Objectives Of The Study 1.2 Geothermal Turbines Market Definition 1.3 Overview 1.4 Limitations 1.5 Markets Covered 2 Geothermal Turbines Market Segmentation 2.1 Geothermal Turbines Market Covered 2.2 Geographical Scope 2.3 Years Considered For The Study 2.4 Currency And Pricing 2.5 Dbmr Tripod Data Validation Model 2.6 Multivariate Modeling 2.7 Primary Interviews With Key Opinion Leaders 2.8 Dbmr Geothermal Turbines Market Position Grid 2.9 Dbmr Vendor Share Analysis 2.1 Secondary Sources 2.11 Assumptions 3 Executive Summary............. Browse Related Reports: https://strategicmarketresearch12.blogspot.com/2024/11/glass-substrate-market-driving.html https://strategicmarketresearch12.blogspot.com/2024/11/gasoline-market-trends-in-production.html https://strategicmarketresearch12.blogspot.com/2024/11/frozen-potato-market-increasing-demand.html https://strategicmarketresearch12.blogspot.com/2024/11/hall-effect-current-sensor-market.html Contact Us: Data Bridge Market Research US: +1 614 591 3140 UK: +44 845 154 9652 APAC : +653 1251 975 Email: corporatesales@databridgemarketresearch.com About Data Bridge Market Research: Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. This release was published on openPR.The Cold Spring Harbor Laboratory, a private research laboratory, is located on Long Island, New York, where I live. Its outrageous history is detailed in a forthcoming book , “Long Island and the Legacy of Eugenics: Station of Intolerance.” The book, by Mark A. Torres, an attorney as well as an author, will be released by The History Press on January 21st. Torres also wrote the 2021 book “Long Island Migrant Labor Camps: Dust for Blood,” an examination of the plight of migrant farmworkers on Long Island, published, too, by The History Press. Torres is general counsel of Teamsters Local 810, a union that covers Long Island, and as an attorney has long specialized in labor and employment law in federal and state courts. He is also a professor at Hofstra University. As an author, he excels at in-depth research. Earlier this year the Association of Public Historians of New York awarded Torres its Joseph F. Meany Award (named for former New York State Historian Joseph F. Meany, Jr.) for his book on migrant farmworker camps on Long Island. Most Long Island residents know little about the Cold Spring Harbor Laboratory although it is off a major highway on Long Island, Route 25A, on 110 acres, and currently employs more than a thousand people. I’ve received an advance copy of Torres’ book. It begins with an “Author’s Note” in which Torres explains: “True to my roots as an author of Long Island history, I have always strived to present topics from the oft-neglected local perspective. Thus, this book is not intended to merely serve as a broad retelling of the history of eugenics. Instead, it focuses on investigating the local origins, characters and stratagems employed by the Eugenics Record Office in Cold Spring Harbor which, for nearly three decades, served as the global headquarters of the eugenics movement.” He relates how his investigative “journey led me to study the archival records at numerous facilities, including the Cold Spring Harbor Laboratory and Archives...the Rockefeller Archive in Sleepy Hollow, New York; the American Philosophical Institute in Philadelphia; Truman State University in Kirksville, Missouri; and the National Museum of Health and Medicine in Silver Springs, Maryland...” “The information I amassed from these meticulously preserved archives provided sharp insight into the origins, inspiration and machinations of the American eugenics movement, while never losing focus on the fact that it all emanated from a small hamlet on Long Island.” “Through it all, I came to understand how eugenics became such an accepted and normalized part of society in the United States and throughout the world during the twentieth century,” writes Torres. He goes on how the book includes “the downfall of the Eugenics Record Office” (part of the Cold Spring Harbor Laboratory between 1910 and 1939) “and the ultimate discrediting of eugenics as a scientific field. The final section also explores the enduring and cruel legacy of eugenics.” “The quest to perfect our species was not a new one,” Torres writes. “However, the problem with such aspirations: Who decides the standards of perfection? And, more importantly, what is to be done with those who fall below the arbitrarily created standards.” Then the book starts with the 1946 trial in Nuremberg, Germany: United States of America v. Karl Brandt, et al. Brandt, who was “the personal physician of Adolph Hitler,” and other doctors were put on trial in the aftermath of World War II for crimes against humanity, he relates, in connection with the Nazi “euthanasia program.” “Brandt and six others were convicted, sentenced to death and executed. Astonishingly, the information that Brandt and his cohorts so desperately relied on for their defense was not derived from Nazi propaganda,” says Torres. “Instead, their sources came directly from a report published in 1914 by the Eugenics Record Office in Cold Spring Harbor, New York.” “What connection,” asks Torres, “did an administrative office four thousand miles away in a small town on Long Island have with the Nazi regime that plotted and carried out the systematic torture and murder of millions of human beings based on race and disability?” “The connection was eugenics: the pseudoscience that dominated much of the twentieth century and was premised on the racist, classist and misguided belief that mental, physical and behavioral traits of human beings were all inheritable and must be eliminated to save the human race.” “Although it was promoted as cutting-edge science, eugenics was a social philosophy that aimed to develop a master race of human beings with the purest blood and the most desirable hereditary traits,” the book continues. A “component” of eugenics was “’negative eugenics’ which aimed to discourage or outright prevent the reproduction of people who were declared genetically unfit. Negative genetics was driven by the premise that society would dramatically improve if the millions of Americans who were deemed mentally, physically or morally undesirable were ‘eliminated from the human stock’ by means of segregation, sterilization and even euthanasia. This included the ‘feebleminded,’ paupers, criminals, epileptics, the insane, the deformed, the congenitally weak, the blind and the deaf. While human heredity would not begin to be understood by scientists until the 1960s, the social prejudice and practice of eugenics dominated scientific objectivity for more than half a century.” “The legacy of eugenics is undeniably cruel and enduring,” writes Torres. “In the United States alone, more than sixty thousand forced sterilizations were carried out in more than half the states....A multitude of people throughout the country were classified as undesirable and confined to psychiatric centers during their childbearing years. A bevy of marriage restriction and eugenic sterilization laws were enacted for the purpose of preventing the procreation of the unfit. Eugenically driven immigration laws barring the entry of immigrants from many countries into the United States endured for years. Globally, eugenics thrived in countries like Argentina, Canada, China, Japan and Norway, and Nazi Germany used it to commit unimaginable atrocities. In some ways, the ideals of eugenics persist today.” “Despite its global appeal,” Torres goes on, “eugenics was truly made in America, and the epicenter of the movement was not found in some laboratory or government facility. Instead, the science was developed at the Eugenics Record Office...in Cold Spring Harbor, Long Island.” Before the Cold Spring Harbor Laboratory became “the global center of the eugenics movement,” eugenics had roots in England, relates Torres. He notes how in 1851 in England, Herbert Spencer penned a book “Social Statics” that “first publicized the phrase survival of the fittest.” And “less than a decade later, Charles Darwin popularized the phrase survival of the fittest in his seminal work “The Origin of the Species.” Yet another Englishman, Francis Galton, a cousin of Darwin, then authored a book “Hereditary Genus” in which he “suggested that the breeding of the best people would evolve mankind into a super species...” “The founding fathers of eugenics in England,” writes Torres, “had formulated the theoretical concepts of human hereditary research. It was only a matter of time before it caught on in the United States, and of the many individuals and groups who helped establish eugenics from theory to practice, none was more influential than an American biologist Charles Davenport who was directly responsible for the establishment and operation of the Eugenics Record Office, which for more than three decades would serve as the eugenics capital of the world.” From the Eugenics Record Office, part of the Cold Spring Harbor Laboratory, “Davenport also led the movement that would ultimately springboard eugenics into a global phenomenon.” “In 1902, the Carnegie Institute of Washington was founded, and Davenport immediately began to lobby the group to invest in the establishment of a center for genetics at Cold Spring Harbor,” Torres continues. And “the forces were beginning to align for the formation of the American eugenics movement, and Charles Davenport would be at the center of it all.” Davenport “developed a plan to collect hereditary information from a multitude of families in order to prove that evolution worked in human beings the way it worked in animals and plants.” In the end, eugenics was thoroughly discredited, as Torres relates in the last chapter of his book, titled “A Reckoning.” “The rise of eugenics was not a random phenomenon,” the chapter begins. “Eugenics presented as a cutting-edge science driven by utopian ideals for the betterment of humanity. It was buoyed by a continuous flow of financial support from wealthy and progressive-minded donors and fully embraced by the leading thinkers of the time before settling into the very fabric of the United States and societies throughout the world. Ultimately, eugenics was discredited as a science and exposed as nothing more than a social philosophy used as a slogan for intolerance, racism, bigotry and classism. It was essentially a means for the wealthy to assert their dominance over the poor, which has been an unfortunate and recurring theme throughout all of human history.” “It took many years for the scientific and corporate communities to accept responsibility for their part in eugenics,” says Torres. Indeed, it was only in 2020 that the president of the Carnegie Institution for Science “issued a formal apology for the group’s support for eugenics.” The statement: “There is no excuse, then or now, for our institution’s previous willingness to empower researchers who sought to pervert scientific inquiry to justify their own racist and ableist prejudices. Our support of eugenics made us complicit in driving decades of brutal and unconscionable actions by the governments in the United States and around the world.” Only in 2023 did the American Society of Human Genetics issue a statement declaring that it “seeks to reckon with, and sincerely apologizes for, its involvement in and silence of the misuse of human genetics to justify and contribute to injustice in all forms,” he continues. Torres closes his book by stating: “In the nearly three decades of its operation, the Eugenics Record Office served as the ultimate vessel to fortify and amplify the pseudoscience called eugenics and transformed it into a global phenomenon. Everything that emanated from this facility served to dominate the poor, the weak and the sick, who were deemed the defectives of society and subject them to mass levels of institutionalization, sterilization, immigration restrictions and even euthanasia. Later, in the hands of the Nazi regime, eugenics was openly used as a scientific excuse to torture and murder a multitude of innocent human beings.” “The Eugenics Record Office and those who directly operated, controlled and funded it are fully deserving of the blame for the entire eugenics movement and the dire atrocities committed under the banner of this false science,” he says. “While we must continue to honor the seemingly countless victims, we must also provide public discourse and educational programs on the subject, for if we fail to do so, we may be in danger of repeating this dark history.” Between the start and end of his book, Torres documents the horrors committed in the name of eugenics—and how an institution on Long Island was the base for it. He names the names—prominent names—including those in government and business in the U.S. who pushed eugenics. “All movements require the support and participation of people with strong public influence” and “there were few greater endorsements than that of president of the United States of America. In fact,” he notes, “every president” of the U.S. from Theodore Roosevelt to Herbert Hoover “was a member of a eugenics organization, publicly endorsed eugenic laws, or signed eugenic legislation without voicing opposition.” As for Roosevelt, whose ”summer White House” at Sagamore Hill was a “mere six miles from the ERO facility in Cold Spring Harbor,” Roosevelt wrote a letter to Davenport asserting: “Someday we will realize that the prime duty of the good citizen of the right type [is] to leave his blood behind him in the world; that that we have no business to perpetuate citizens of the wrong type.” He tells of John Harvey Kellogg, a doctor who with his brother founded the Kellogg company that developed corn flakes becoming a “staunch ally of Charles Davenport and a full-fledged eugenicist....In 1914, he organized the First Race Betterment Foundation Conference in Battle Creek, Michigan, with the stated purpose of establishing the foundations for the creation of a super race.” On its website, Cold Spring Harbor Laboratory in a section labeled its “History” has an essay on a “historical perspective on genetics” headlined: “Good genes, bad science.” It begins relating how in the early 1900s “the bogus concept of hereditary criminality and a made-up disease known as feeblemindedness became part of some scientists’ so-called studies of genetics. Ideas such as these were the core of the American eugenics movement....in which science got mixed up with racial dogma. Among the results was the destruction of thousands of people’s ability to pass on their ‘defective’ genes through forced sterilization programs.” “Many of Hitler’s beliefs were directly inspired by the eugenics books he read while he was in prison,” writes Torres. (Hitler was jailed for leading in 1923 the Beer Hall Putsch, an attempted coup in Munich involving members of his Nazi Party. Convicted of treason, he was sentenced to five years in jail and served nine months.) Hitler “admired,” Torres continues, “the policies of the American eugenics program, including the efforts that led to the passage of strict immigration laws in the United States.” In 1933, he “seized power,” and “eugenics presented Hitler with a...globally accepted science to support his sinister plans. In July 1933, Germany enacted the ‘Law for the Prevention of Defective Progeny,’ the first eugenic sterilization law in the country....The law also established approximately two hundred genetic courts and managed anyone suspected of having a genetic defect to be reported to the authorities.” A publication put out by the Eugenics Record Office, Eugenical News, featured the law “proudly.” Soon, “German eugenicists began to formulate definitions of Jewishness. Hitler insisted that Jews of all degrees to be identified, including those with at least one drop of Jewish blood.” The “methodology was fully inspired by the family pedigree system created at Cold Spring Harbor Laboratory more than two decades before,” writes Torres. With the mass sending of Jews and others to death camps, Hitler “directed...doctors at different concentration camps to conduct a wide range of eugenics-based research.” “Over time, the world began to learn of the Nazis’ atrocities,” writes Torres. “In 1936, the Rockefeller Foundation finally became reluctant to fund any further eugenics-based programs, and nearly all funding ended when the fighting erupted in 1939. Unfortunately, Nazi eugenics programs had already benefited from the foundation’s funding, and the fully developed program continued throughout the war.” The book includes a chapter on the impact of eugenic advocates on U.S. immigration law, titled “’Scientific Racism’ and the Anti-Immigration Movement.” Torres writes about how Harry Laughlin, superintendent of the Eugenics Record Office from its inception to closure, sent a report to the U.S. Congress in 1922 labeling certain immigrants “human waste.” Writes Torres: “Page after page, the report was rife with racial and ethnic slurs and detailed statistics regarding feeblemindedness, insanity, crime, various forms of illness and deformity and ‘all types of social inadequacy.’” Laughlin testified before Congress in 1922 asserting: “These degeneracies and hereditary handicaps are inherent in the blood.” Before Congress again, in 1924, “elaborate charts” were displayed by Laughlin “promoting the link between the so-called inferior races and immoral conduct.” “As a direct result of Laughlin’s tireless efforts, which were driven by his eugenic ideals coupled with lawmakers’ growing racial animus against immigrants, the House and Senate passed the Immigration Act of 1924,” writes Torres. “The law imposed even stricter quotas on immigrants from all non-Nordic nations. For example, the quota on immigration from Italy was dramatically reduced from forty-two thousand per year to just four thousand.” In the U.S., laws were passed to mandate sterilization based on the claims of eugenics. Torres focuses on a 1927 U.S. Supreme Court 8-to-1 decision upholding a “request by the State of Virginia to forcefully sterilize nineteen-year-old Carrie Buck based on a eugenics diagnosis.” She was determined to be “feebleminded.” The ruling, written by Justice Oliver Wendell Holmes, Jr. “has never been reversed,” writes Torres. “It is an enduring legacy left by the Eugenics Record Office and a direct byproduct of the ERO’s work. In the wake of the decision, the number of sterilizations across the country began to grow exponentially.” The Eugenics Record Office activities also included research close to home, “in local communities on Long Island and throughout New York State.” It got involved with psychiatric institutions on Long Island including Kings Park Psychiatric Center, Central Islip State Hospital and Pilgrim State Hospital in Brentwood. The book includes how “Native American reservations on Long Island were targeted” by Davenport and his followers including what is now the Shinnecock Indian Nation and the Unkechaug Reservation, both on Long Island. He tells of how Dr. John Strong, the author of numerous books on Native Americans and long a professor of history at Southampton College on Long Island, said “the eugenically biased data derived from these studies was used by the [U.S.] Bureau of Indian Affairs...to the detriment of the Native American population.” Torres in an interview emphasized how eugenics “was not a fringe movement. It was the rage of the age. It was widely embraced.” Torres writes of how eugenics was embraced by academia in the U.S. “During much of the early to mid-twentieth century, eugenics was taught....at the most prestigious academic institutions in the country, including Harvard, Johns Hopkins, Princeton and Yale.” He cites a 1916 ERO report stating that 254 colleges taught courses about eugenics. He writes: “At Boston University, eugenics was taught to students at the School of Theology.” New York University, Columbia and Barnard “each offered a eugenics-based course....Other New York colleges that taught eugenics” that are listed include Adelphi, Cornell, Colgate, Farmingdale, Fordham, Syracuse University and Vassar. Also, he notes, “eugenics was a regularly offered course in the biology department at San Francisco State University from 1916 to 1951.” The year 1951 was decades after the Eugenics Records Office at Cold Spring Harbor Laboratory was shut down. In recent years, what eugenics is about has continued as an issue. In 2007, Dr. James Watson, chancellor of the Cold Spring Harbor Laboratory and a Nobel Prize winner, was relieved of his post after saying in an interview with the London Times that that there was an intelligence gap between Blacks and whites and this accounted for many of problems in Africa. In 2019, the laboratory stripped Watson of titles he still held including chancellor emeritus after he appeared on a PBS documentary “American Masters: Decoding Watson,” and, asked if he changed his views, said: “No. Not at all....there’s a difference on the average between Blacks and whites on I.Q tests. I would say the difference is....genetic.” Last month, Laura Helmuth, editor-in-chief of Scientific American, resigned after complaints about comments she made including, online, that “Trump’s racist rants are straight-up eugenics.” An article in the magazine in October scored Donald Trump’s statements about immigrants, its headline “Trump’s Racist Rants against Immigrants Hide under the Language of Eugenics.” Helmuth from 2016 to 2018 was president of the National Association of Science Writers. And this month, New York magazine featured an article headlined: “A Rift in the Family, My in-laws gave me a book by a eugenicist. Our relationship is over.”The best is yet to come. That’s the annual rallying cry for NHL teams above the playoff bar at the quarter pole to secure their positions. And especially for those who need to beat historical odds to advance to the second season. It’s rare for teams out of the wild-card chase after 20 games to make the playoff grade. It requires a strong run of success to catch and then pass other contenders and also hold regulation wins and tie-breaker advantages. Brock Boeser did more than his part last season to ensure the Canucks had a memorable regular season and took their best playoff shot as Pacific Division champions. The right winger had a career-high 40 goals and deployed a complete game. And now that Boeser is on verge of returning from a Nov. 7 concussion, he will be a key cog to help the Canucks get back to the dance. He practised Monday in a full contact jersey and might play Tuesday in Boston. “It felt great,” said Boeser. “It’s hard to not be in game shape, but they pushed me pretty hard. It’s really hard to judge until you step into that first game. Short shifts and control it that way.” Last season in the Western Conference, two teams in wild-card positions at the quarter pole — St. Louis and Seattle — didn’t make the playoff cut, while those below that bar — Edmonton and Nashville — advanced. The Oilers did it in stunning fashion to finish with 104 points, five back of the Canucks. And the Predators secured the first wild-card spot for a postseason date with the Canucks. In the Eastern Conference, Washington and the Islanders were out of playoff contention at the quarter pole but rallied. The Capitals were the second wild-card seed, while the Islanders had a finishing 8-1-1 kick to place third in the Metropolitan Division. What does this mean for the Canucks? They were one point out of a wild-card spot Monday with 23 points (10-6-3) after 19 games, but held games in hand on Colorado and the Oilers, who were seeded first and second. The Canucks were in a much more comfortable position a year ago with a 14-7-1 record and a point out of the division lead. It’s hard to imagine these Canucks won’t gain ground as they get healthier. They were five points shy of the division lead Monday with two games in hand and can close that gap on this six-game trip because a 7-1-0 mark away from home has kept them competitive. Here’s the good and bad we’ve learned at the quarter pole: Saving the day: General manager Patrik Allvin should be on the next Vegas stop. He made a wise $875,000 US bet on free-agent acquisition Kevin Lankinen to hold the goaltending fort while Thatcher Demko nears a return from a knee-muscle injury. The handsome return has been Lankinen’s tidy 9-3-2 record, 2.74 goals-against average, .901 saves percentage, and a shutout. It also gave Arturs Silovs a longer runway to gather his game and get through losing Jiri Patera to a waiver claim and then the re-claim. Really winging it: Pushing the pace for more off the rush meant adding Jake DeBrusk, Danton Heinen, Kiefer Sherwood and rolling the dice on the mercurial Daniel Sprong. He could dash but not defend, and was traded to Seattle on Nov. 8 for future considerations. DeBrusk is hitting scoring stride, Heinen is good on the penalty kill, and Sherwood has been a wise bet. Drove the Canucks crazy in the playoffs. Has six goals, 12 points, a league-leading 125 hits, and is on the books for another year at just $1.5 million. Grinding on road: Away from home distractions and better dialled into systems have been beyond promising. Only Minnesota has just one regulation loss on the road (9-1-3) and the numbers really reflect how the Canucks are sold on the process. In a 7-1-0 run, they hold a 29-17 goal advantage, are 6-for-24 on the power play (24 per cent) and 22-for-27 on the penalty kill for 81.1 per cent efficiency. House of horrors: The Canucks were 27-9-5 at home last season and their paltry 3-5-3 mark this season stings. Slow starts, especially at home, meant coughing up the first goal on 10 occasions in an 11-game span. And with the Canucks 0-5-1 overall when trailing after two periods, and 6-0-2 when leading after 40 minutes, you can see where the big problem is. Can’t script this: Testicular cancer surgery, no Vezina Trophy finalist, no 40-goal scorer and no 103-point winger is a test of collective resolve. Dakota Joshua missed the first 14 games with his procedure, Demko is nearing a return from knee rehab, Boeser may play Tuesday, and J.T. Miller could be back after this trip from an indefinite leave of absence. Yes, defence wins: A year ago, the camp message put an accent on positional play. Be good in your own zone and transition should lead to offence. With four new wingers at camp this season, it was about creating more odd-man rushes because the back end should be fine. However, three new blueliners in the mix and a struggling second pair have hurt defending. bkuzma@postmedia.com

( ), ( ) and Mitsubishi on Monday confirmed they are in talks regarding a possible merger at a time of auto industry upheaval. Honda stock tried to regain a key level on Tuesday after jumping on the merger news. The possible three-way merger would see Japan's second and third biggest carmakers join forces, along with smaller Mitsubishi. That combination would create the world's third largest automaker by annual sales, behind only Japanese peer Toyota Motor ( ) and German giant Volkswagen ( ). Embattled car giants Honda and Nissan hope to stave off falling sales and intensifying competition. Their joint statement on Monday alluded to "dramatic changes in the environment surrounding both companies and the automotive industry," a likely reference to these powerful forces gaining strength: : Legacy auto giants are in the middle of a massive shift from gas and diesel cars to electric and hybrid vehicles in a bid to lower polluting emissions. Newer vehicles are also increasingly software defined. All this adds up to steep development costs. By merging, Honda and Nissan could jointly develop such vehicles and use common platforms to share and optimize costs. Cost saving is especially important for the co right now. Both Honda and Nissan's sales are in a sharp two-year slump. Honda posted a steep quarterly profit drop in November, mainly due to a challenging Chinese market. : Chinese EV makers continue to rise in the domestic and overseas markets. China dominates global EV supply chains and subsidizes its EV industry, with its automakers churning out affordable electric cars. Affordable doesn't necessarily mean cheap. Chinese EV giant ( ) and its startup peers, including ( ) and ( ), make technology-driven electric cars. Korean EV makers like Hyundai and Kia are also on the rise. By comparison, Japan's auto giants are trying to catch up in fully battery electric vehicles, though they are leaders in hybrid cars. A merger could improve efficiencies in their EV investments. : Analysts at Morgan Stanley identified a third force forcing Honda and Nissan to consider a merger: the rise of semi autonomous or fully autonomous vehicles. Tesla and some of its Chinese rivals are the clear leaders in vehicle autonomy, with . Maturing autonomous technologies have placed Nissan and Honda under new pressure to fund AI and software development, the Morgan Stanley analysts said. They noted Tesla's doubling to $1.5 trillion market capitalization in the span of six weeks, adding: "If the age of autonomy has truly arrived, then things will move very fast from here." Honda Stock, Nissan Stock And EV Stocks Shares of Honda Motor popped nearly 1% in Tuesday's . Honda stock tested the falling 50-day moving average after jumping nearly 13% on Monday after the possible merger confirmation. The stock has dropped 28% from a March high, and carries a very weak IBD Composite Rating of 38. Nissan stock popped more than 7% on Friday, extending its rally above the 50-day line and giving it a 27% gain for December. Tesla stock climbed 5%, extending Monday's rally on solid EV delivery news. China EV stocks, including Tesla archrival BYD, traded broadly higher.David Coote will not appeal against the termination of his contract by referees’ body PGMOL, the PA news agency understands. Coote was sacked earlier this month after the emergence of a video in which he made derogatory remarks about Liverpool and their former manager Jurgen Klopp. Professional Game Match Officials Limited (PGMOL) said that a thorough investigation had concluded he was “in serious breach of the provisions of his employment contract, with his position deemed untenable”. “Supporting David Coote continues to be important to us and we remain committed to his welfare,” PGMOL’s statement on December 9 added. Coote had the right to appeal against the decision but PA understands the Nottinghamshire referee has decided not to. The video which triggered PGMOL’s investigation into Coote’s conduct first came to public attention on November 11. In it, Coote is asked for his views on a Liverpool match where he has just been fourth official, and describes them as “s***”. He then describes Klopp as a “c***”, and, asked why he felt that way, Coote says the German had “a right pop at me when I reffed them against Burnley in lockdown” and had accused him of lying. “I have got no interest in speaking to someone who’s f****** arrogant, so I do my best not to speak to him,” Coote said. Later in the video, Coote again refers to Klopp, this time as a “German c***”. The Football Association opened its own investigation into that video, understood to be centred on that last comment and whether Coote’s reference to Klopp’s nationality constituted an aggravated breach of its misconduct rules. The investigation by PGMOL which led to Coote’s contract being terminated is also understood to have looked at another video which appeared to show Coote snorting a white powder, purportedly during Euro 2024 where he was one of the assistant VARs for the tournament. European football’s governing body UEFA also appointed an ethics investigator to look into the matter.2 rescued after California wharf partially collapses due to heavy surf from major Pacific storm

DORAL, Fla.--(BUSINESS WIRE)--Dec 23, 2024-- NeueHealth, Inc. (“NeueHealth” or the “Company”) (NYSE: NEUE), the value-driven healthcare company, today announced that it has entered into a definitive merger agreement pursuant to which the Company will be acquired by an affiliate of New Enterprise Associates (“NEA”) at an enterprise value of approximately $1.3 billion. Upon completion of the transaction, NeueHealth will become a privately held company with the flexibility and resources to continue advancing its value-driven, consumer-centric care model. Under the terms of the merger agreement, holders of NeueHealth common stock (other than shares that will be rolled over and certain excluded shares) will receive $7.33 per share in cash, which represents a premium of approximately 70% over the closing price of NeueHealth common stock on December 23, 2024. Certain stockholders of NeueHeath, including NEA and 12 existing NeueHealth investors (which collectively hold all of the outstanding shares of NeueHealth preferred stock), have entered into rollover agreements pursuant to which such stockholders will continue their investments by exchanging their shares of NeueHealth common stock and/or preferred stock for newly issued equity interests in the privately held company, and the Company’s existing secured loan facility with Hercules Capital, Inc. will remain in place. NeueHealth’s executive leadership team will continue in their roles upon completion of the transaction and intends to roll over 100% of their equity interests for newly issued equity interests in the privately held company. “We are pleased to announce this transaction as we believe it places NeueHealth in a strong position for continued growth while maximizing value for all of NeueHealth’s public stockholders,” said Mike Mikan, President and CEO of NeueHealth. “NEA has been a longstanding strategic partner, and we look forward to continuing to work together to build on NeueHealth’s success as a leader in value-based care.” “We believe NeueHealth has built a differentiated model of care that is uniquely positioned to drive value for consumers, providers, and payors and we have confidence in the NeueHealth team and their ability to continue to lead the Company,” said Mohamad Makhzoumi, Co-CEO of NEA. “We have had a strong partnership with NeueHealth since 2016 and share the Company’s commitment to making high-quality healthcare accessible and affordable for all Americans.” Transaction Details A special committee (the “Special Committee”) of the board of directors of NeueHealth (the “Board”), composed entirely of independent and disinterested directors and advised by its own independent legal and financial advisors, unanimously recommended that the Board approve the transaction and determined it was in the best interests of the Company and its stockholders that are not affiliated with NEA. Acting upon the recommendation of the Special Committee, the Board subsequently unanimously approved the transaction and determined to recommend that NeueHealth stockholders vote to approve and adopt the merger agreement. Certain NeueHealth stockholders have agreed to vote all of their shares of NeueHealth common stock and/or preferred stock to approve and adopt the merger agreement, subject to certain conditions. The merger is subject to approval by NeueHealth’s stockholders and other customary closing conditions, including receipt of certain regulatory approvals. NEA intends to finance the transaction with fully committed equity financing, and the transaction is not subject to any financing condition. Upon completion of the transaction, NeueHealth’s common stock will no longer be publicly traded or listed on any public market. The merger agreement includes a 30-day “go-shop” period that will expire at 12:01 AM New York City time on January 23, 2025, which permits the Special Committee and its financial advisors to solicit and consider alternative acquisition proposals. There can be no assurance that this process will result in a superior proposal, and NeueHealth does not intend to disclose developments with respect to the “go-shop” process unless and until it determines such disclosure is appropriate or is otherwise required. Lincoln International, LLC is acting as financial advisor, and Richards, Layton & Finger, P.A. is acting as legal counsel, to the Special Committee. Simpson Thacher & Bartlett LLP is acting as legal counsel to NeueHealth. Latham and Watkins LLP is acting as legal counsel to NEA, with Sidley Austin LLP acting as insurance regulatory counsel to NEA. More information regarding the key terms will be included in a current report on Form 8-K to be filed by NeueHealth with the Securities and Exchange Commission (the “SEC”). Important Information and Where to Find It In connection with the transaction, the Company will file with the SEC a proxy statement on Schedule 14A (the “Proxy Statement”), the definitive version of which will be sent or provided to Company stockholders. The Company, affiliates of the Company and affiliates of NEA intend to jointly file a transaction statement on Schedule 13E-3 (the "Schedule 13E-3") with the SEC. The Company may also file other documents with the SEC regarding the transaction. This release is not a substitute for the Proxy Statement, the Schedule 13E-3 or any other document which the Company may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT, THE SCHEDULE 13E-3 AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE COMPANY OR THE TRANSACTION BECAUSE THESE DOCUMENTS CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement, the Schedule 13E-3 and other documents that are filed or will be filed with the SEC by the Company, when such documents become available, through the website maintained by the SEC at www.sec.gov or through the Company's website at https://investors.neuehealth.com/home/default.aspx . The transaction will be implemented solely pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024 (the “merger agreement”), among the Company, NH Holdings 2025, Inc. and NH Holdings Acquisition 2025, Inc., which contains the full terms and conditions of the transaction. Participants in the Solicitation The Company and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from stockholders of the Company in connection with the proposed transaction. Information regarding the Company’s directors and executive officers is available in the definitive proxy statement for the 2024 annual meeting of stockholders of the Company, which was filed by the Company with the SEC on April 1, 2024 (the “Annual Meeting Proxy Statement”), and will be available in the Proxy Statement. Please refer to the sections captioned “Executive Compensation,” “Director Compensation,” and “Security Ownership of Certain Beneficial Owners and Management” in the Annual Meeting Proxy Statement. Holdings of the Company’s securities by certain of the Company’s employees, and any changes in the holdings of the Company’s securities by the Company’s directors or executive officers from the amounts described in the Annual Meeting Proxy Statement, have been reflected in the following Statements of Change in Ownership on Form 4 filed with the SEC: Form 4, filed by George Lawrence Mikan III on May 6, 2024; Form 4, filed by Jay Matushak on May 6, 2024; Form 4, filed Tomas Orozco on May 6, 2024; Form 4, filed by Jeffery Michael Craig on May 6, 2024; Form 4, filed by Jeffrey J. Scherman on May 6, 2024; Form 4, filed by Jay Matushak on May 13, 2024; Form 4, filed by Jeffrey J. Scherman on May 13, 2024; Form 4, filed by Kedrick D. Adkins, Jr. on May 14, 2024; Form 4, filed by Andrew M. Slavitt on May 14, 2024; Form 4, filed by Linda Gooden on May 14, 2024; Form 4, filed by Mohamad Makhzoumi on May 14, 2024; Form 4, filed by Robert J. Sheehy on May 14, 2024; Form 4, filed by Matthew G. Manders on May 14, 2024; Form 4, filed by Stephen Kraus on May 14, 2024; Form 4, filed by Manuel Kadre on May 14, 2024; Form 4, filed by Jeffrey R. Immelt on May 14, 2024; Form 4, filed by Mohamad Makhzoumi on October 3, 2024; Form 4, filed by Jay Matushak on October 8, 2024; Form 4, filed by George Lawrence Mikan III on December 18, 2024. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in connection with the proposed transaction when they become available. Free copies of the Proxy Statement and such other materials may be obtained as described in the preceding paragraph. About NeueHealth NeueHealth is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated care. By uniquely aligning the interests of health consumers, providers, and payors, NeueHealth helps to make healthcare accessible and affordable to all populations across the ACA Marketplace, Medicare, and Medicaid. NeueHealth delivers high-quality clinical care to over 500,000 health consumers through owned clinics and unique partnerships with over 3,000 affiliated providers. We also enable independent providers and medical groups to thrive in performance-based arrangements through a suite of technology and services scaled centrally and deployed locally. We believe our value-driven, consumer-centric care model can transform the healthcare experience and maximize value across the healthcare system. For more information, visit: www.neuehealth.com . About NEA New Enterprise Associates (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has more than $25 billion in assets under management as of June 30, 2024 and invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of investing includes more than 280 portfolio company IPOs and more than 465 mergers and acquisitions. For more information, please visit www.nea.com . Forward-Looking Statements This release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, and statements as to the expected timing, completion and effects of the transaction. These statements often include words such as “anticipate,” “expect,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “projections,” “outlook,” “ensure,” and other similar expressions. These forward-looking statements include any statements regarding our plans, expectations and financial guidance. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: the failure to complete the transaction on the anticipated terms and within the anticipated timeframe, including as a result of failure to obtain required stockholder or regulatory approvals or to satisfy other closing conditions; potential litigation relating to the transaction that could be instituted against NEA, the Company or their respective affiliates, directors, managers, officers or employees, and the effects of any outcomes related thereto; potential adverse reactions or changes to our business relationships or operating results resulting from the announcement, pendency or completion of the transaction; the risk that our stock price may decline significantly if the transaction is not consummated; certain restrictions during the pendency of the transaction that may impact our ability to pursue certain business opportunities or strategic transactions; costs associated with the transaction, which may be significant; the occurrence of events, changes or other circumstances that could give rise to the termination of the merger agreement, including in circumstances requiring us to pay a termination fee; our ability to continue as a going concern; our ability to comply with the terms of our credit facilities­ or any credit facility into which we enter in the future; our ability to receive the remaining proceeds from the sale of our Medicare Advantage business in California in a timely manner; our ability to obtain any short or long term debt or equity financing needed to operate our business; our ability to quickly and efficiently complete the wind down of our remaining Individual and Family Plan (“IFP”) and MA businesses, including by satisfying liabilities of those businesses when due and payable; potential disruptions to our business due to the transaction or due to corporate restructuring and any resulting headcount reduction; our ability to accurately estimate and effectively manage the costs relating to changes in our business offerings and models; a delay or inability to withdraw regulated capital from our subsidiaries; a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our and our care partner’s abilities to obtain and accurately assess, code, and report risk adjustment factor scores; our ability to contract with care providers and arrange for the provision of quality care; our ability to obtain claims information timely and accurately; the impact of any pandemic or epidemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage any growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions, integrate acquired businesses, and quickly and efficiently divest businesses as needed; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; our ability to adapt to mitigate risks associated with our ACO businesses, including any unanticipated market or regulatory developments; and the other factors set forth under the heading “Risk Factors” in the Company’s reports on Form 10-K, Form 10-Q, and Form 8-K (including all amendments to those reports) and our other filings with the SEC. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations. View source version on businesswire.com : https://www.businesswire.com/news/home/20241223595862/en/ CONTACT: Investor Contact: IR@neuehealth.comMedia Contact: media@neuehealth.com KEYWORD: FLORIDA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: PRACTICE MANAGEMENT PROFESSIONAL SERVICES MANAGED CARE HEALTH GENERAL HEALTH HEALTH TECHNOLOGY HEALTH INSURANCE HOSPITALS INSURANCE TELEMEDICINE/VIRTUAL MEDICINE FINANCE SOURCE: NeueHealth Copyright Business Wire 2024. PUB: 12/23/2024 05:53 PM/DISC: 12/23/2024 05:53 PM http://www.businesswire.com/news/home/20241223595862/en